Evidence map›Paper›PMID 30393502›Full record

ArticleArchives of medical science : AMS2018

Comparative effects of methylprednisolone and tetracosactide (ACTH

Hayri Kertmen, Erhan Celikoglu, Ozden Caglar Ozturk, Bora Gürer, Huseyin Bozkurt, Mehmet Ali Kanat, Ata Turker Arikok, Berrin Imge Erguder, Mustafa Fevzi Sargon, Zeki Sekerci

Open access · goldAbstract read
In one paragraph

Article in Archives of medical science : AMS, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Hayri KertmenNeurosurgery Clinic, Diskapi Yildirim Beyazit Education and Research Hospital, Ministry of Health, Ankara, Turkey.
Erhan CelikogluNeurosurgery Clinic, Fatih Sultan Mehmet Education and Research Hospital, Ministry of Health, Istanbul, Turkey.
Ozden Caglar OzturkNeurosurgery Clinic, Mardin Nusaybin State Hospital, Ministry of Health, Mardin, Turkey.
Bora GürerNeurosurgery Clinic, Fatih Sultan Mehmet Education and Research Hospital, Ministry of Health, Istanbul, Turkey.
Huseyin BozkurtDepartment of Neurosurgery, Faculty of Medicine, Cumhuriyet University, Sivas, Turkey.
Mehmet Ali KanatRefik Saydam National Public Health Agency, Ministry of Health, Ankara, Turkey.
Ata Turker ArikokDepartment of Pathology, Diskapi Yildirim Beyazit Education and Research Hospital, Ministry of Health, Ankara, Turkey.
Berrin Imge ErguderDepartment of Biochemistry, Faculty of Medicine, Ankara University, Ankara, Turkey.
Mustafa Fevzi SargonDepartment of Anatomy, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Zeki SekerciNeurosurgery Clinic, Diskapi Yildirim Beyazit Education and Research Hospital, Ministry of Health, Ankara, Turkey.
Ministry of Health · TRAnkara University · TRDışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi · TRFatih Sultan Mehmet Eğitim Ve Araştırma Hastanesi · TRHacettepe University · TRSivas Cumhuriyet Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionTetracosactide is an engineered peptide that applies the same biological impacts as the endogenous adrenocorticotropic hormone. Previous studies indicated that tetracosactide has anti-inflammatory, antioxidant and neurotrophic activity. In this study, we hypothesized that tetracosactide may have protective effects in spinal cord ischemia-reperfusion injury. MATERIAL AND

methodsRabbits were randomized into the accompanying four groups of eight animals each: group 1 (control), group 2 (ischemia), group 3 (methylprednisolone) and group 4 (tetracosactide). In the control group, just a laparotomy was performed. In the various groups, the spinal cord ischemia model was made by the impediment of the aorta only caudal to the renal vein. Neurological assessment was conducted with the Tarlov scoring system. Levels of myeloperoxidase, malondialdehyde and catalase were analyzed, similar to the activities of xanthine oxidase and caspase-3. Histopathological and ultrastructural assessments were additionally performed.

resultsAfter ischemia-reperfusion injury, increments were found in the tissue myeloperoxidase levels (

conclusionsThe findings showed for the first time that tetracosactide shows significant neuroprotective activity against ischemia-reperfusion injury of the spinal cord.

Indexed as

adrenocorticotropic hormoneischemia-reperfusionmethylprednisoloneneuroprotectionspinal cordtetracosactide

Identifiers

PMID30393502
PMCPMC6209702
OpenAlexW2589078995

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.